NEW YORK – Ambry Genetics and Tempus said Tuesday that they have entered into a strategic collaboration to offer a combined comprehensive, germline and somatic testing service.
Under the agreement, Ambry is performing germline sequencing assays for Tempus, powered by Ambry's next-generation sequencing CancerNext and CancerNext-Expanded assays, which identify genetic variants associated with hereditary cancer syndromes and inherited risk of cancer.
These will be incorporated into the germline tests that Tempus currently offers, Tempus xG and xG+, which are part of a larger portfolio of oncology-focused testing solutions including solid tumor and liquid biopsy panels, along with algorithmic-based tests for the assessment of homologous recombination deficiency and the prediction of tumor of origin.
Financial terms of the agreement were not disclosed.
"Tempus has a powerful offering for tissue and liquid biopsy DNA and RNA profiling and somatic testing. Now, with our germline testing and variant assessment expertise behind Tempus xG and xG+, we are poised to create a future where paired somatic and germline testing is the standard,” Ambry Chief Operating Officer Brigette Tippin Davis said in a statement.
The deal follows a recent commercialization agreement between Tempus and sequencing firm Personalis, under which the companies are working to bring Personalis' minimal residual disease detection technology to the clinic.